NewAmsterdam Pharma (NAMS) Income from Continuing Operations (2023 - 2026)

NewAmsterdam Pharma has disclosed Income from Continuing Operations across 4 years of filings, most recently posting 48441000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 48441000.0, down 22.55% year-over-year; the trailing twelve-month figure through Mar 2026 was 212733000.0 (down 351.41% YoY), and the FY2025 annual result was 203819000.0, down 101.07% from the prior year.
• Income from Continuing Operations came in at 48441000.0 for Q1 2026 at NewAmsterdam Pharma, up from 74923000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 48055000.0 in Q4 2024 to a low of 93767000.0 in Q1 2024.
• The 4-year median for Income from Continuing Operations is 42018000.0 (2023), against an average of 40810461.54.
• Across the five-year window, Income from Continuing Operations surged 197.14% in 2024 and tumbled 332.54% in 2025, its largest moves.
• NewAmsterdam Pharma's Income from Continuing Operations stood at 49468000.0 in 2023, then soared by 197.14% to 48055000.0 in 2024, then sank by 255.91% to 74923000.0 in 2025, then soared by 35.35% to 48441000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 48441000.0 (Q1 2026), 74923000.0 (Q4 2025), and 72005000.0 (Q3 2025), per Business Quant data.